|
|
Volumn 12, Issue 1, 2009, Pages 83-87
|
|
Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LEUPRORELIN;
PROSTATE SPECIFIC ANTIGEN;
TESTOSTERONE;
AGED;
ARTICLE;
CANCER HORMONE THERAPY;
CANCER RADIOTHERAPY;
CANCER RELAPSE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG DOSAGE FORM COMPARISON;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
EUROPE;
FATIGUE;
HOT FLUSH;
HUMAN;
INJECTION SITE INDURATION;
INJECTION SITE REACTION;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
OPEN STUDY;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATECTOMY;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SWEATING;
TUMOR GROWTH;
UNSPECIFIED SIDE EFFECT;
AGED;
ANTINEOPLASTIC AGENTS;
DELAYED-ACTION PREPARATIONS;
EUROPE;
FOLLICLE STIMULATING HORMONE;
HUMANS;
LEUPROLIDE;
LUTEINIZING HORMONE;
MALE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
TESTOSTERONE;
|
|
EID: 60349128936
PISSN: 13657852
EISSN: 14765608
Source Type: Journal
DOI: 10.1038/pcan.2008.52 Document Type: Article |
|
Times cited : (31)
|
|
References (9)
|
